ClinicalTrials.gg
RecruitingNCT05748158POWERSUpdated Jun 12, 2026

A Study to Investigate Why Overweight People Regain Weight After Losing Weight in a Behavioral Weight Loss Program

An interventional study of Weight loss in Obesity, sponsored by University of Pittsburgh. Recruiting at 3 sites in United States. Open to participants aged 25 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
205
Allocation
Not applicable
Ages
25 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Obesity by University of Pittsburgh — 2 open to participants now, 7 under way, none of them phase 3. Obesity · University of Pittsburgh.

Planned enrollment
16th of 49
205 · median 75
Started
2023
with 2 others
No phase
37 of 60
2 open now
Registered
58th of 60
by date

Among the 60 studies in Obesity by University of Pittsburgh, this one is the 16th largest by planned enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2023, is one of 37 with no phase, and was the 58th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 60 studies in Obesity by University of Pittsburgh are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 25 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Obesity by University of Pittsburgh, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the physiological basis for the differences in weight regain among adults (25-59 years old) with obesity following participation in a behavioral weight loss program. Eligible participants will undergo a baseline evaluation after which they will enter an up to 20 week behavioral weight loss program with the goal of losing at least 7 percent of their baseline weight within 35 weeks. Participants who meet the weight loss goal will be asked to remain weight stable for 2 weeks after which they will undergo a clinical examination. They will then be observed for 1 year during which they will undergo 2 additional clinical examinations, one 4 months after completing the weight loss program, and the other 12 months after completing the weight loss program.

Read the detailed description

Primary Hypothesis:

Changes, integrated values and patterns in energy intake (EI), energy expenditure (EE), resting energy expenditure (REE) and non-resting energy expenditure (NREE), contribute to the variability in weight change during the 12 months following weight loss.

Assessment time points:

  • Baseline (BL): prior to starting the weight loss intervention
  • T0: at the end of a period of weight stabilization following at least 7 percent weight loss
  • T4: four months (17 weeks) following T0
  • T12: twelve months (52 weeks) following T0

Secondary Hypotheses:

Changes, integrated values and patterns in components of EI and EE (listed below) contribute to variability in weight change during the 12 months following weight loss.

EI:

  • Psychosocial, food attitude, and food environment assessments
  • Diet composition
  • Neural activation in food choice/decision-making and cue/taste/reward (functional magnetic resonance imaging [fMRI])
  • Measures of food choice, delay discounting, and eating in the absence of hunger
  • Gastric emptying, appetite-related peptides, and glucose and lipid excursions in response to a meal

EE:

  • Physical activity
  • 24-hour urine catecholamine
  • Muscle contractile efficiency
  • Mitochondrial function in biopsied skeletal muscle
  • Sleep quality and patterns

    • Muscle and adipose tissue gene expression
    • Plasma metabolome, proteome, exosomes and exposome
    • Stool microbiome

Specific Aims:

Specific Aim 1: Examine total energy expenditure (TEE) and energy intake (EI) at, and between, baseline, the end of the weight stabilization period following at least 7 percent weight loss, 17 weeks and 52 weeks after the end of the weight stabilization period following at least 7 percent weight loss with respect to variability in weight change between the end of the weight stabilization period following at least 7 percent weight loss and 52 weeks after the end of the weight stabilization period following at least 7 percent weight loss.

Specific Aim 2: Examine resting energy expenditure (REE) and non-resting energy expenditure (NREE) at, and between, baseline, the end of the weight stabilization period following at least 7 percent weight loss, 17 weeks and 52 weeks after the end of the weight stabilization period following at least 7 percent weight loss with respect to variability in weight change between the end of the weight stabilization period following at least 7 percent weight loss and 52 weeks after the end of the weight stabilization period following at least 7 percent weight loss.

Specific Aim 3: Assess endophenotypes of EI (e.g. diet composition, food-choice, decision-making, delay discounting, cue/taste reward, gastric emptying, appetite-related peptides, glucose and lipid excursions in response to a meal, sleep patterns, food and social environments) at and between time points at which they are measured (e.g., baseline, the end of the weight stabilization period following at least 7 percent weight loss, 17 weeks and 52 weeks after the end of the weight stabilization period following at least 7 percent weight loss) and examine their contributions to the variability in weight change between the end of the weight stabilization period following at least 7 percent weight loss and 52 weeks later.

Specific Aim 4: Assess endophenotypes of EE (e.g., actigraphy measures, sleep patterns, muscle contractile efficiency, mitochondrial function, muscle and adipose tissue gene expression, plasma metabolome, microbiome, exposome, and environment) at, and between, time points at which they are measured (e.g., baseline, the end of the weight stabilization period following at least 7 percent weight loss, 17 weeks and 52 weeks after the end of the weight stabilization period following at least 7 percent weight loss) and examine their contributions to the variability in weight change between the end of the weight stabilization period following at least 7 percent weight loss and 52 weeks later.

03

Conditions studied

  • Obesity

Keywords

  • Obesity
  • Weight loss
  • Weight change trajectory
  • Lifestyle intervention
04

Who can participate

Ages eligible
25 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 25 - \<60 years
  2. : 30 - \<40 kg/m2 at the first screening visit
  3. Within 5% of current weight, for the past 6 months at the first screening visit
  4. Able to participate in ergometry testing
  5. Has a smart phone, tablet or computer with access to the internet

Exclusion criteria

Exclusion Criteria:

  1. If 25-29 years old, > 5% deviation from maximum weight (excluding weights while pregnant) since age 25 years
  2. If at least 30 years old, > 5% deviation from maximum weight (excluding weights while pregnant) in last 5 years or ≥ 10% deviation from maximum weight (excluding weights while pregnant) since age 30 years
  3. History of pulmonary embolus in the past 6 months
  4. Cardiovascular disease (e.g. myocardial infarction, stroke, hospitalization for unstable angina, or ) within the past 6 months
  5. Current major depressive disorder or history of major depressive disorder within 2 years
  6. Any regular tobacco or nicotine use in the past year
  7. Currently engaging in intense physical training or training for a sports event including, but not limited to, a marathon or body building
  8. Currently pregnant, or less than one-year post-partum or actively planning to become pregnant within the next two years
  9. Presently classified as being in Class II or greater or dysrhythmia
  10. Diabetes (type 1 or 2 - ≥ 6.5%, fasting glucose ≥ 126 mg/dL) or currently taking a glucose lowering medication
  11. Thyroid disease requiring hormones or medication or TSH \< 0.5 or > 5 mIU/L
  12. Renal disease requiring dialysis
  13. Known infection
  14. or AST greater than 5 times the or active gall bladder disease
  15. Significant anemia ( \< 10 g/dL) or thrombocytopenia ( count \< 60,000 /mm3)
  16. Leukopenia defined as:

    Males: WBC \< 3,100 /mm3 or (WBC 3,100 - \< 4,000 /mm3 and at least 1 Duffy antigen (A, B) positive or no result) Females: WBC \< 3,400 /mm3 or (WBC 3,400 - \< 4,000 /mm3 and at least 1 Duffy antigen (A, B) positive or no result)

  17. Active cancer or current chemotherapy treatment, or history of cancer requiring treatment in the past 5 years except for non-melanoma skin cancers or cancers that have clearly been cured
  18. Current or past history of anorexia nervosa or bulimia nervosa
  19. Current or past diagnosis of binge eating disorder
  20. Diagnosis of other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder)
  21. Unwillingness to abstain from marijuana/cannabis use for 3 weeks at each of the four assessment time points
  22. Known or suspected abuse or misuse of alcohol, prescription drugs, or recreational drugs
  23. Antiretroviral therapy (ART), including treatment for HIV, pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) within the past 3 months
  24. Regularly taking medication or supplement known to affect appetite, energy expenditure, or weight (e.g. appetite suppressants, -including inhaled steroids but not topical, alpha-blockers, beta-blockers, certain psychotropic medications)
  25. Currently taking anticoagulant medication
  26. Currently enrolled in a supervised weight reduction program
  27. Prior or planned bariatric surgery, endoscopic therapy, device-based therapy for obesity, liposuction, cryolipolysis, or abdominoplasty
  28. Severely restricted diets: Vegan (no meat, fish, dairy, eggs, or honey), very low carbohydrate (\<15% calorie as carbohydrate), very low fat (\<15% calories as fat), or strictly gluten free
  29. Current celiac or diagnosed gluten intolerance or inflammatory bowel disease requiring specialized diet
  30. Night or rotating shift worker
  31. Known severe allergy (e.g. anaphylaxis) to nuts or other foods
  32. Systolic blood pressure (BP) \<90 mmHg and/or diastolic BP \<60 mmHg on 2 measurements during the clinical screening visit.
  33. Systolic blood pressure (BP) >160 mmHg and/or diastolic BP >100 mmHg on at least 2 measurements during the clinical screening visit or resting heart rate \< 45 beats per minute or >100 on 2 measurements during the clinical screening visit.
  34. Metal implants, piercings that cannot be removed, or metal-based tattoos or hair treatments
  35. Exceeds limitations to fit dual-energy X-ray absorptiometry (DXA) field of view
  36. Known allergy to lidocaine or acetaminophen
  37. Non-compliance with appointments or tasks (food diaries, etc.) during the screening phase
  38. Blood clotting disorder or > ULN or PT > ULN or (a)PTT > ULN
  39. Tendency to form thick or raised scars
  40. Inability to achieve weight stability (defined in section 4.2.1) during the 2 weeks prior to initiation of the baseline Doubly Labeled Water (DLW) assessment
  41. At high risk for suicide, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
205 participants (estimated)

Study arms

  • Other
    Weight loss

    A 37 week behavioral intervention aimed at decreasing energy intake and increasing physical activity.

    Behavioral: Weight loss

Interventions

  • BehavioralWeight loss

    A behavioral lifestyle program, up to 20 weeks in duration, based on interventions shown to be successful for weight loss such as the Diabetes Prevention Program (DPP), Action for Health in Diabetes (Look AHEAD), and Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy Study (CALERIE). Weekly sessions, led by experienced interventionists, will provide education and behavioral strategies for weight loss focused an energy-reduced diet and physical activity. Participants must meet the following milestones to continue in the study: * ≥ 2% weight loss anytime between 28 and 34 days after the start of the intervention * ≥ 5% weight loss anytime between 140 and 146 days after the start of the intervention * ≥ 7% weight loss by the end of 35 weeks After achieving ≥7% weight loss followed by weight stability, participants are observed, without further intervention, for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Weight change from end of weight stabilization following at least 7 percent weight loss to 52 weeks after weight stabilization following at least 7 percent weight loss

    Percentage of lost weight that is regained

    Time frame: End of weight stabilization following at least 7 percent weight loss vs. 52 weeks after weight stabilization following at least 7 percent weight loss

  2. Weight change from end of weight stabilization following at least 7 percent weight loss to 52 weeks after weight stabilization following at least 7 percent weight loss

    Weight regained

    Time frame: End of weight stabilization following at least 7 percent weight loss vs. 52 weeks after weight stabilization following at least 7 percent weight loss

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Relevant individual participant data (IPD) will be provided to approved ancillary study investigators. All data will be archived, following the end of the study, at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-supported data repository.

Supporting information: Study protocol

Time frame: Following the end of data collection. Time frame is determined by the NIDDK.

Access criteria: Access to the data for approved ancillary studies will be through the data coordinating center. Access to the data at the NIDDK-repository will be through the NIDDK data repository's process.

Data sharing details ↗ · repository.niddk.nih.gov

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Mar 2027, 42 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 42 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2023
First posted
Feb 28, 2023
StartActual
Sep 29, 2023
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05748158
Responsible party
Steven Belle (Professor, University of Pittsburgh) — Principal investigator
First posted
Feb 28, 2023
Start date
Sep 29, 2023
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jun 12, 2026

Study contacts

Stephanie Kelley, MS, CCRP
Contact
Kelleys@edc.pitt.edu
412-624-9487
Steven Belle, PhD
principal investigator · University of Pittsburgh
Dympna Gallagher, EdD
principal investigator · Columbia University
Susan Roberts, PhD
principal investigator · Dartmouth College

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion